# AmerisourceBergen Corporation – Consensus ‘buy’ rating and 16.2% Upside Potential

- Link: https://www.directorstalkinterviews.com/amerisourcebergen-corporation-consensus-buy-rating-and-16.2-upside-potential-2/4121126241
- Published: 2023-08-30T13:22:00+01:00
- Author: Charlotte Edwards

**AmerisourceBergen Corporation** which can be found using ticker (ABC) have now
14 market analysts covering the stock. The analyst consensus now points to a rating
of ‘buy’. The range between the high target price and low target price is between
225 and 190 and has a mean target at $209.57. Now with the previous closing price
of $180.39 and the analysts are correct then we can expect a percentage increase
in value of 16.2%. The day 50 moving average is $187.51 and the 200 day MA is $170.17.
The total market capitalization for the company now stands at 36.15B. The stock 
price is currently at: 179.98 USD

 The potential market cap would be $41,997,301,323 based on the market consensus.

The company has a dividend yield of 1.09%. Other points of data to note are a P/
E ratio of 21.92, revenue per share of 1247.29 and a 2.7% return on assets.

AmerisourceBergen Corporation is a global pharmaceutical sourcing and distribution
services company. The Company’s U.S. Healthcare Solutions segment distributes an
offering of brand-name, specialty brand-name and generic pharmaceuticals, over-the-
counter healthcare products, home healthcare supplies and equipment, and related
services to a wide variety of healthcare providers, including acute care hospitals
and health systems, independent and chain retail pharmacies, mail order pharmacies,
medical clinics, long-term care and alternate site pharmacies, and other customers.
The International Healthcare Solutions segment consists of businesses that focus
on international pharmaceutical wholesale and related service operations and global
commercialization services. This segment consists of Alliance Healthcare, World 
Courier, Innomar, Profarma, and Profarma Specialty. The Company also focuses on 
specialty services and a global platform of pharma manufacturer services capabilities.

Share on:
